{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-25-000142","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.460988+00:00","generated_at":"2026-05-17T01:58:14.744144+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcutis Q3 2025 net product revenue $99.2M (+122% YoY); turns profitable; FY2026 guidance $455-470M","bullets":["Net product revenue $99.2M (+122% YoY, +22% sequential); driven by ZORYVE cream and foam.","Net income $7.4M ($0.06 EPS) vs net loss $41.5M ($0.33 loss per share) in Q3 2024.","FDA approved ZORYVE cream 0.05% for atopic dermatitis in children 2-5; launch by end of October.","Initial FY2026 net product revenue guidance of $455-$470M; peak ZORYVE sales target $2.6-3.5B.","Phase 2 trials started for ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-25-000142","json":"https://secwatch.observer/filing/0001787306-25-000142.json","markdown":"https://secwatch.observer/filing/0001787306-25-000142.md","text":"https://secwatch.observer/filing/0001787306-25-000142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000142/0001787306-25-000142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000142/arqt-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:58:14.744144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}